Welcome To Nutrify Snips

Nutra News made Easy

  • Vitamin D and Probiotics: A New Strategy for Managing Migraines

    A recent clinical trial investigating the effects of vitamin D and probiotic co-supplementation on migraines yielded positive results among 72 participants aged 18 to 55 diagnosed with migraines. Those receiving vitamin D (50,000 IU biweekly) and probiotics (4.5 × 10¹¹ CFU daily) experienced a significant increase in serum vitamin D levels, averaging a rise of 12.86 ng/mL… Read More


  • Spermidine: The Polyamine with Potential for a Healthier Heart!

    Spermidine, a naturally occurring polyamine, shows promise in promoting heart health by potentially lowering cardiovascular disease (CVD) risk factors. A recent study utilizing a bi-directional Mendelian randomization approach found that higher spermidine levels are significantly associated with reduced risk of hypertension, lower blood glucose levels, and improved lipid profiles—demonstrated by decreased low-density lipoprotein cholesterol (LDL-C)… Read More


  • BluNAD Booster Enhances NAD Production and Regulates Degrading Enzymes in Clinical Trial

    The recently completed randomized, double-blind, placebo-controlled trial involved 140 participants, divided into four groups of 35, who were assigned to receive either BluNAD Booster, an NAD precursor, a combination of both, or a placebo. Researchers evaluated the treatment’s impact on NAD-boosting activity through blood biomarkers, physical performance measures, and quality of life assessments. Initial findings… Read More


  • Olive Mill Wastewater: A Potential Nutraceutical from a Byproduct

    Olive oil is renowned for its health benefits, attributed to its rich content of healthy fats and bioactive compounds with antioxidant and anti-inflammatory properties. However, the production of olive oil generates a substantial amount of waste, including olive mill wastewater (OMW), a byproduct previously regarded as harmful. OMW contains high levels of organic and phenolic… Read More


  • Silymarin Reduces Liver Stiffness in MASLD Patients by Modulating Gut Microbiota: A 24-Week Randomized Controlled Trial

    A 24-week randomized, double-blind, placebo-controlled trial investigated the effect of silymarin on liver stiffness in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Eighty-three participants were divided between a silymarin group (103.2 mg/day) and a placebo group. Results showed that silymarin significantly reduced liver stiffness, γ-glutamyl transpeptidase (GGT), and ApoB levels compared to placebo. However,… Read More


Join the biggest platform for nutraceuticals